Skip to main content
TVRD
NASDAQ Life Sciences

Tvardi Therapeutics Reports Positive Phase 1 Results for TTI-109, Confirming Prodrug Design and Target Engagement

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
9
Price
$2.17
Mkt Cap
$18.857M
52W Low
$1.5
52W High
$43.65
52W Position info
45% above low
Off High info
95% below high
Rel. Volume info
0.5× avg
Market data snapshot near publication time

TVRD sits 45% above its 52-week low of $1.5.

Summary

Tvardi Therapeutics reported positive Phase 1 clinical data for its STAT3 inhibitor TTI-109, showing improved tolerability and target engagement, paving the way for Phase 2 studies in dermatologic and GI diseases, pending additional funding.


Key Events · Product Development and Regulatory · TVRD

  • Positive Phase 1 TTI-109 Results

    The study confirmed rapid prodrug conversion, equivalent exposure to TTI-101, sustained target-level exposure, and improved tolerability compared to TTI-101.

  • Evidence of STAT3 Target Engagement

    Exploratory pharmacodynamic analysis showed reductions of up to 60% in STAT3-driven immune cell populations, including Th17, T follicular helper (Tfh), and B cells.

  • Advancement to Phase 2 Planned

    The company plans to advance TTI-109 into STAT3-driven dermatologic and gastrointestinal diseases, subject to additional funding.

  • Investor Webcast Scheduled

    Tvardi management will host an investor webcast today, July 7, 2026, to discuss these results in more detail.


Analysis · TVRD · Life Sciences

Tvardi Therapeutics announced positive Phase 1 clinical trial results for TTI-109, its next-generation STAT3 inhibitor. The study confirmed successful prodrug conversion, improved tolerability compared to TTI-101, and significant pharmacodynamic evidence of STAT3 target engagement, with reductions in disease-relevant immune cell populations. These results validate the company's development strategy and support advancing TTI-109 into Phase 2 studies for dermatologic and gastrointestinal diseases. This positive clinical data is crucial for the micro-cap biotech, especially given its prior going concern warning and existing ATM program, as it directly impacts its ability to secure the additional funding required for further development.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 52.4% of the 208 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -1.91%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, TVRD was trading at $2.17 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $18.9M. The 52-week trading range was $1.50 to $43.65. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

TVRD - Latest Insights

TVRD
Nov 13, 2026, 7:10 AM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $1.11
Real-time Price: $0.934 info
Change: -$0.1766 (-16%) info
Market Cap: $12.294M info
TVRD
Nov 13, 2026, 7:05 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.11
Real-time Price: $0.934 info
Change: -$0.1766 (-16%) info
Market Cap: $12.294M info
TVRD
Aug 14, 2026, 7:10 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $1.82
Real-time Price: $0.934 info
Change: -$0.886 (-49%) info
Market Cap: $12.294M info
TVRD
Aug 14, 2026, 7:05 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.82
Real-time Price: $0.934 info
Change: -$0.886 (-49%) info
Market Cap: $12.294M info
TVRD
Aug 14, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $1.82
Real-time Price: $0.934 info
Change: -$0.886 (-49%) info
Market Cap: $12.294M info